Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 1-2/2015

01.01.2015 | original article

No evidence for desmocollin 3 to serve as a prognostic marker in primary radiotherapy of head and neck cancer

verfasst von: MD Dominik Riss, MD Johannes Pammer, MD, MME Matthaeus C. Grasl, MSc Alexandra Kaider, MD Sven Schneider, MD, PD Boban M. Erovic

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 1-2/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Purpose

To investigate the role of desmocollin 3 expression in radiation sensitivity and survival in squamous cell carcinoma of the head and neck.

Methods

Tissue samples of 40 patients undergoing primary radiotherapy were stained for desmocollin 3, a transmembrane desmosomal protein. The protein expression was determined by immunohistochemistry. A retrospective chart review was performed to assess overall survival, radiation sensitivity, and disease-free interval.

Results

18 of 40 patients showed desmocollin 3 immunoreactivity. 78 % (14/18) showed radiation sensitivity in the desmocollin 3 positive group, whereas 59 % (13/22) underwent remission in the desmocollin 3 negative group (p = 0.2). The median overall and disease-free survival time was 21 and 26 months, respectively. Univariate and multivariable Cox regression models revealed no statistically significant hazard ratios.

Conclusion

In this cohort of squamous cell carcinoma of the head and neck, we found no evidence for a predictive potential of desmocollin 3.
Literatur
1.
Zurück zum Zitat Hardman MJ, Liu K, Avilion AA, et al. Desmosomal cadherin misexpression alters beta-catenin stability and epidermal differentiation. Mol Cell Biol. 2005;25(3):969–78. doi:10.1128/MCB.25.3.969-978.2005. PubMedCentralPubMedCrossRef Hardman MJ, Liu K, Avilion AA, et al. Desmosomal cadherin misexpression alters beta-catenin stability and epidermal differentiation. Mol Cell Biol. 2005;25(3):969–78. doi:10.1128/MCB.25.3.969-978.2005. PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Fang WK, Gu W, Li EM, et al. Reduced membranous and ectopic cytoplasmic expression of DSC2 in esophageal squamous cell carcinoma: an independent prognostic factor. Hum Pathol. 2010;41(10):1456–65. doi:10.1016/j.humpath.2010.04.003. PubMedCrossRef Fang WK, Gu W, Li EM, et al. Reduced membranous and ectopic cytoplasmic expression of DSC2 in esophageal squamous cell carcinoma: an independent prognostic factor. Hum Pathol. 2010;41(10):1456–65. doi:10.1016/j.humpath.2010.04.003. PubMedCrossRef
4.
Zurück zum Zitat Oshiro MM, Kim CJ, Wozniak RJ, et al. Epigenetic silencing of DSC3 is a common event in human breast cancer. Breast Cancer Res. 2005;7(5):R669–80. doi:10.1186/bcr1273. PubMedCentralPubMedCrossRef Oshiro MM, Kim CJ, Wozniak RJ, et al. Epigenetic silencing of DSC3 is a common event in human breast cancer. Breast Cancer Res. 2005;7(5):R669–80. doi:10.1186/bcr1273. PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Wang L, Liu T, Wang Y, et al. Altered expression of desmocollin 3, desmoglein 3, and beta-catenin in oral squamous cell carcinoma: correlation with lymph node metastasis and cell proliferation. Virchows Arch. 2007;451(5):959–66. doi:10.1007/s00428-007-0485-5. PubMedCrossRef Wang L, Liu T, Wang Y, et al. Altered expression of desmocollin 3, desmoglein 3, and beta-catenin in oral squamous cell carcinoma: correlation with lymph node metastasis and cell proliferation. Virchows Arch. 2007;451(5):959–66. doi:10.1007/s00428-007-0485-5. PubMedCrossRef
6.
Zurück zum Zitat Hamidov Z, Altendorf-Hofmann A, Chen Y, Settmacher U, Petersen I, Knosel T. Reduced expression of desmocollin 2 is an independent prognostic biomarker for shorter patients survival in pancreatic ductal adenocarcinoma. J Clin Pathol. 2011;64(11):990–4. doi:10.1136/jclinpath-2011-200099. PubMedCrossRef Hamidov Z, Altendorf-Hofmann A, Chen Y, Settmacher U, Petersen I, Knosel T. Reduced expression of desmocollin 2 is an independent prognostic biomarker for shorter patients survival in pancreatic ductal adenocarcinoma. J Clin Pathol. 2011;64(11):990–4. doi:10.1136/jclinpath-2011-200099. PubMedCrossRef
7.
Zurück zum Zitat Klus GT, Rokaeus N, Bittner ML, et al. Down-regulation of the desmosomal cadherin desmocollin 3 in human breast cancer. Int J Oncol. 2001;19(1):169–74. PubMed Klus GT, Rokaeus N, Bittner ML, et al. Down-regulation of the desmosomal cadherin desmocollin 3 in human breast cancer. Int J Oncol. 2001;19(1):169–74. PubMed
8.
Zurück zum Zitat Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48(1):7–16. PubMedCrossRef Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48(1):7–16. PubMedCrossRef
9.
Zurück zum Zitat Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–6. PubMedCrossRef Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–6. PubMedCrossRef
10.
Zurück zum Zitat Erovic BM, Pelzmann M, Grasl M, et al. Mcl-1, vascular endothelial growth factor-R2, and 14-3-3sigma expression might predict primary response against radiotherapy and chemotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Clin Cancer Res. 2005;11(24 Pt 1):8632–6. doi:11/24/8632. [pii] 10.1158/1078-0432.CCR-05–1170. PubMedCrossRef Erovic BM, Pelzmann M, Grasl M, et al. Mcl-1, vascular endothelial growth factor-R2, and 14-3-3sigma expression might predict primary response against radiotherapy and chemotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Clin Cancer Res. 2005;11(24 Pt 1):8632–6. doi:11/24/8632. [pii] 10.1158/1078-0432.CCR-05–1170. PubMedCrossRef
11.
Zurück zum Zitat Langer CJ. Exploring biomarkers in head and neck cancer. Cancer. 2012;118(16):3882–92. doi:10.1002/cncr.26718. PubMedCrossRef Langer CJ. Exploring biomarkers in head and neck cancer. Cancer. 2012;118(16):3882–92. doi:10.1002/cncr.26718. PubMedCrossRef
12.
Zurück zum Zitat van den Broek GB, Wildeman M, Rasch CR, et al. Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer. 2009;124(11):2643–50. doi:10.1002/ijc.24254. PubMedCrossRef van den Broek GB, Wildeman M, Rasch CR, et al. Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer. 2009;124(11):2643–50. doi:10.1002/ijc.24254. PubMedCrossRef
13.
Zurück zum Zitat Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36. doi:10.3322/caac.20121. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36. doi:10.3322/caac.20121.
14.
Zurück zum Zitat Tselepis C, Chidgey M, North A, Garrod D. Desmosomal adhesion inhibits invasive behavior. Proc Natl Acad Sci U S A. 1998;95(14):8064–9. Tselepis C, Chidgey M, North A, Garrod D. Desmosomal adhesion inhibits invasive behavior. Proc Natl Acad Sci U S A. 1998;95(14):8064–9.
15.
Zurück zum Zitat Chen J, O’Shea C, Fitzpatrick JE, Koster MI, Koch PJ. Loss of desmocollin 3 in skin tumor development and progression. Mol Carcinog. 2012;51:535–45. doi:10.1002/mc.20818. Chen J, O’Shea C, Fitzpatrick JE, Koster MI, Koch PJ. Loss of desmocollin 3 in skin tumor development and progression. Mol Carcinog. 2012;51:535–45. doi:10.1002/mc.20818.
16.
Zurück zum Zitat Rezze GG, Fregnani JH, Duprat J, Landman G. Cell adhesion and communication proteins are differentially expressed in melanoma progression model. Hum Pathol. 2011;42(3):409–18. doi:S0046-8177(10)00313-8 [pii] 10.1016/j.humpath.2010.09.004. PubMedCrossRef Rezze GG, Fregnani JH, Duprat J, Landman G. Cell adhesion and communication proteins are differentially expressed in melanoma progression model. Hum Pathol. 2011;42(3):409–18. doi:S0046-8177(10)00313-8 [pii] 10.1016/j.humpath.2010.09.004. PubMedCrossRef
17.
Zurück zum Zitat Kurzen H, Munzing I, Hartschuh W. Expression of desmosomal proteins in squamous cell carcinomas of the skin. J Cutan Pathol. 2003;30(10):621–30. PubMedCrossRef Kurzen H, Munzing I, Hartschuh W. Expression of desmosomal proteins in squamous cell carcinomas of the skin. J Cutan Pathol. 2003;30(10):621–30. PubMedCrossRef
18.
Zurück zum Zitat Boelens MC, van den Berg A, Vogelzang I, et al. Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus. J Clin Pathol. 2007;60(6):608–14. doi:jcp.2005.031443 [pii] 10.1136/jcp.2005.031443. PubMedCentralPubMedCrossRef Boelens MC, van den Berg A, Vogelzang I, et al. Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus. J Clin Pathol. 2007;60(6):608–14. doi:jcp.2005.031443 [pii] 10.1136/jcp.2005.031443. PubMedCentralPubMedCrossRef
Metadaten
Titel
No evidence for desmocollin 3 to serve as a prognostic marker in primary radiotherapy of head and neck cancer
verfasst von
MD Dominik Riss
MD Johannes Pammer
MD, MME Matthaeus C. Grasl
MSc Alexandra Kaider
MD Sven Schneider
MD, PD Boban M. Erovic
Publikationsdatum
01.01.2015
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 1-2/2015
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-014-0618-1